Sun Pharmaceuticals

Infobox Company
name = Sun Pharmaceuticals

type = Public (Bombay Stock Exchange: [http://www.bseindia.com/price_finder/stockreach.asp?scripcd=524715 ticker=SUN] )
genre =
foundation = Mumbai, India 1983)
founder =
location_city = flagicon|India Mumbai, India
location_country =
location =
locations =
area_served =
key_people =
industry = Pharmaceuticals
products =
services =
market c

revenue = profitRs.21.320 billion INR (2007)
operating_income =
net_income = profitRs.7.842.7 billion INR (2007)
assets =
equity =
owner =
num_employees = 7000 (2007) }
homepage = [http://www.sunpharma.com/ www.sunpharma.com]

Sun Pharmaceuticals (or Sun Pharmaceuticals Industries Limited) (Bombay Stock Exchange symbol:SUN) is an international pharmaceutical company based in Mumbai, India. It makes many generic and brand name drugs that are distributed in the United States, Europe, Asia and worldwide. [ [http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?symbol=SUN.BO Sun Pharmaceutical Industries Ltd. (SUN.BO): Stock Quote & Company Profile - BusinessWeek ] ] Sun manufactures both pharmaceuticals and active pharmaceutical ingredients (API), in essence, ingredients to be used in finished pharmaceutical products. Its products are in several therapeutic areas, including psychiatry, neurology, cardiology, diabetology, gastroenterology, respiratory, and orthopedics.

History

Established in 1983, Sun Pharma was a start-up company with five products. Since 1996, Sun has grown largely through a combination of internal growth, and acquisition of other pharmaceutical companies. For example, it bought US-based Caraco Pharm Labs, and ICN Hungary.

A planned acquisition of Israeli Taro Pharmaceuticals initiated in March 2007 was terminated by the Taro board in May 2008; [cite news | author=staff | title=Sun Takes Over Taro for $454M | url= | format=print
work=Genetic Engineering & Biotechology News | publisher=Mary Ann Liebert, Inc. | page=10 | date=2007-06-15
accessdate=2008-07-06 ] [cite press release
title=Taro Terminates Merger Agreement with Sun Pharmaceutical Industries Ltd. | publisher=Taro Pharmaceuticals
date=2008-05-28 | url=http://phx.corporate-ir.net/phoenix.zhtml?c=114698&p=irol-newsArticle&ID=1151068&highlight=
accessdate=2008-07-06 ] this was subsequently followed by an unsolicited tender offer in June 2008, the outcome of which remains to be determined. [cite press release
title=Taro Board of Directors to Evaluate Unsolicited Tender Offer From Sun Pharmaceutical Industries Ltd.
publisher=Taro Pharmaceuticals | date=2008-06-30
url=http://phx.corporate-ir.net/phoenix.zhtml?c=114698&p=irol-newsArticle&ID=1170752&highlight=
accessdate=2008-07-06 ]

As of 2008, it has grown to become an international speciality pharma company with more than 7000 employees, 17 manufacturing locations worldwide, two research centers, and a presence in 30 countries. It is one of the leading Indian-based pharma companies in India. [IMS-ORG Stockist Audit, August 2007]

Corporate Structure

The company's overall management is the responsibility of its Board comprised of:

Dilip S. Shanghvi, Chairman and Managing Director. Mr. Shanghvi founded the company in 1982.

Sudhir V. Valia Executive Director Sailesh T. Desai Executive Director Hasmukh S. Shah Non-Executive Independent Director Keki M. Mistry Non-Executive Independent Director Ashwin Dani Non-Executive Independent Director

References